JP2018525447A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525447A5
JP2018525447A5 JP2018530646A JP2018530646A JP2018525447A5 JP 2018525447 A5 JP2018525447 A5 JP 2018525447A5 JP 2018530646 A JP2018530646 A JP 2018530646A JP 2018530646 A JP2018530646 A JP 2018530646A JP 2018525447 A5 JP2018525447 A5 JP 2018525447A5
Authority
JP
Japan
Prior art keywords
compound
halogenated
optionally
formula
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018530646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525447A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/049271 external-priority patent/WO2017035529A1/en
Publication of JP2018525447A publication Critical patent/JP2018525447A/ja
Publication of JP2018525447A5 publication Critical patent/JP2018525447A5/ja
Pending legal-status Critical Current

Links

JP2018530646A 2015-08-27 2016-08-29 App選択的bace阻害のための組成物およびそのための使用 Pending JP2018525447A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210945P 2015-08-27 2015-08-27
US62/210,945 2015-08-27
PCT/US2016/049271 WO2017035529A1 (en) 2015-08-27 2016-08-29 Compositions for app-selective bace inhibition and uses therfor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020152650A Division JP2021001188A (ja) 2015-08-27 2020-09-11 App選択的bace阻害のための組成物およびそのための使用

Publications (2)

Publication Number Publication Date
JP2018525447A JP2018525447A (ja) 2018-09-06
JP2018525447A5 true JP2018525447A5 (enExample) 2019-08-29

Family

ID=58101012

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018530646A Pending JP2018525447A (ja) 2015-08-27 2016-08-29 App選択的bace阻害のための組成物およびそのための使用
JP2020152650A Pending JP2021001188A (ja) 2015-08-27 2020-09-11 App選択的bace阻害のための組成物およびそのための使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020152650A Pending JP2021001188A (ja) 2015-08-27 2020-09-11 App選択的bace阻害のための組成物およびそのための使用

Country Status (8)

Country Link
US (1) US11142505B2 (enExample)
EP (1) EP3341362B1 (enExample)
JP (2) JP2018525447A (enExample)
KR (1) KR20180090778A (enExample)
CN (1) CN108349905A (enExample)
AU (1) AU2016311502B2 (enExample)
CA (2) CA2996542C (enExample)
WO (1) WO2017035529A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3653609B1 (en) * 2013-02-12 2024-04-03 Buck Institute for Research on Aging Hydantoins that modulate bace-mediated app processing
JP2018525447A (ja) 2015-08-27 2018-09-06 ナントネウロ,エルエルシー App選択的bace阻害のための組成物およびそのための使用
WO2019169183A1 (en) * 2018-03-01 2019-09-06 The Regents Of The University Of Califorinia Amyloid protein-selective bace inhibitors (asbis) for alzheimer's disease
US11926599B1 (en) 2023-10-23 2024-03-12 King Faisal University 1-(2-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione as an antimicrobial compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06507782A (ja) 1990-06-15 1994-09-08 サイオス ノバ インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
AU652997B2 (en) 1991-01-21 1994-09-15 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
DE69233109T2 (de) 1992-01-07 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Transgene tiermodelle fur alzheimer-krankheit
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
ES2318902T3 (es) 1998-09-24 2009-05-01 PHARMACIA & UPJOHN COMPANY LLC Secretasa en la enfermedad del alzheimer.
CA2579724A1 (en) * 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
BRPI0613578A2 (pt) 2005-06-30 2012-01-17 Wyeth Corp composito da fórmula i; uso de um composto de fórmula i; e composição farmacêutica
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
RU2008106936A (ru) * 2005-09-26 2009-11-10 Вайет (Us) Соединения амино-5-[4-(дифторметокси)фенил]-5-фенилимидазолона для ингибирования бета-секретазы
JP2009520027A (ja) 2005-12-19 2009-05-21 ワイス 2−アミノ−5−ピペリジニルイミダゾロン化合物およびβ−セクレターゼ調節におけるその使用
PE20090617A1 (es) * 2007-03-23 2009-05-08 Wyeth Corp Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
EP3653609B1 (en) 2013-02-12 2024-04-03 Buck Institute for Research on Aging Hydantoins that modulate bace-mediated app processing
US9980769B2 (en) 2014-04-08 2018-05-29 Ethicon Llc Methods and devices for controlling motorized surgical devices
JP2018525447A (ja) 2015-08-27 2018-09-06 ナントネウロ,エルエルシー App選択的bace阻害のための組成物およびそのための使用
US20200165225A1 (en) 2017-06-28 2020-05-28 Nantbio, Inc. Bace1 inhibitors for treatment of alzheimer's disease
WO2019169183A1 (en) * 2018-03-01 2019-09-06 The Regents Of The University Of Califorinia Amyloid protein-selective bace inhibitors (asbis) for alzheimer's disease

Similar Documents

Publication Publication Date Title
de Boer et al. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study
JP2016040288A5 (enExample)
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2015511638A5 (enExample)
JP2013513613A5 (enExample)
JP2018518537A5 (enExample)
JP2013501731A5 (enExample)
JP2009533356A5 (enExample)
JP2017524005A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2008534453A5 (enExample)
JP2016503797A5 (enExample)
JP2019516739A5 (enExample)
JP2009511568A5 (enExample)
CN105228622B (zh) 用于治疗多发性硬化的PPARγ激动剂
JP2015535247A5 (enExample)
JP2010532383A5 (enExample)
JP2018535989A5 (enExample)
JP2019520344A5 (enExample)
RU2008139195A (ru) Замещенные арилсульфанамиды как противовирусные средства
JP2020500868A5 (enExample)
RU2019111421A (ru) Способы лечения острого повреждения почек
JP2016537338A5 (enExample)
JP2016537432A5 (enExample)
JP2015522077A5 (enExample)